Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Update

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the target of a large decline in short interest in February. As of February 15th, there was short interest totalling 7,100 shares, a decline of 61.8% from the January 31st total of 18,600 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average trading volume of 11,000 shares, the days-to-cover ratio is presently 0.6 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Armata Pharmaceuticals in a research note on Thursday, December 19th.

Armata Pharmaceuticals Stock Performance

ARMP traded down $0.01 during trading on Friday, reaching $2.07. 1,854 shares of the company’s stock were exchanged, compared to its average volume of 10,168. The firm has a market capitalization of $74.93 million, a PE ratio of -1.26 and a beta of 0.87. Armata Pharmaceuticals has a fifty-two week low of $1.80 and a fifty-two week high of $4.48.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.